Clinical Advances in Lung Cancer
This Disease Education Center is intended to update clinicians with the latest breakthroughs in the treatment and management of lung cancer.
December 4, 2019
The FDA accepted a supplemental Biologics License Application for durvalumab and granted it priority review for the treatment of patients with previously untreated extensive-stage small cell lung cancer...
December 1, 2019
When added to standard chemotherapy, combination therapy with durvalumab and the anti-CTLA4 antibody tremelimumab results in positive progression-free survival rates among patients with previously untreated stage IV non-small cell lung cancer ...
November 13, 2019
Is it possible for diet to play a role in the development of lung cancer among never-smokers? According to the results of a new analysis, the answer seems to be a resounding yes.
November 11, 2019
New research has found that high levels of NaPi2b expression are prevalent in adenocarcinoma histology, as well as across a range of adenocarcinoma subtypes in patients with early stage, surgical non small-cell lung cancer.
November 7, 2019
A multi-center team of researchers may have found a novel application for the protease inhibitor nelfinavir mesylate (Viracept, Pfizer) in patients with locally advanced non small-cell lung cancer...